Catherine M. Gordon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Catherine M. Gordon has a total of 177 co-authors. Here are the top co-authors by number of shared publications:
Henry A. Feldman
6 shared publicationsAmy D. DiVasta
Children’s Hospital Boston
3 shared publicationsAvery LeBoff Williams
Division of Adolescent Medicine (C.M.G., A.L.W., J.M., L.S.), Children’s Hospital Boston, Boston, Massachusetts 02115
3 shared publications- Sarah Jean Emans
Division of Adolescent/Young Adult Medicine, Children's Hospital, Boston, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts
3 shared publications - Amy Desrochers DiVasta
Division of Adolescent Medicine, Children's Hospital Boston, Boston, MA 02115, USA
2 shared publications - Bill G. Kapogiannis
National Institutes of Health, Bethesda, MD, United States
2 shared publications
Latest Publications
- Open Access
- 1 July 2023
- Published by IATED Academy in EDULEARN Proceedings
- Vol. 1, 8140
PICTURE THIS: EVALUATING HEALTHCARE EDUCATION USING STUDENT GENERATED PICTORIAL DATA
- 1 July 2023
- Published by IATED Academy in EDULEARN Proceedings
- Vol. 1, 8140
Open AccessPICTURE THIS: EVALUATING HEALTHCARE EDUCATION USING STUDENT GENERATED PICTORIAL DATA
- 8 June 2021
- Published by Springer Nature in Pediatric Research
- Vol. 92 (6) , 1520-1526
Academic pipeline initiatives in pediatrics
- 8 June 2021
- Published by Springer Nature in Pediatric Research
- Vol. 92 (6) , 1520-1526
Academic pipeline initiatives in pediatrics
- 8 June 2020
- Published by Wolters Kluwer Health in Clinical Obstetrics & Gynecology
- Vol. 63 (3) , 504-511
Adolescents and Bone Health
Adolescence is a critical time for the acquisition of peak bone mass. There are modifiable factors that may influence bone health in an adolescent. For those at risk for bone fragility, initial management includes optimization of calcium and vitamin D, weight-bearing exercise, and maintenance of a normal body weight. In certain scenarios, bisphosphonate treatment is indicated, as is reviewed. How hormonal contraceptives affect bone mineral density is unclear, but in patients with risk factors or known bone fragility, prescribers should consider their skeletal effects. Some conditions, including restrictive eating disorders and primary ovarian insufficiency, warrant long-term monitoring of bone health.
- 8 June 2020
- Published by Wolters Kluwer Health in Clinical Obstetrics & Gynecology
- Vol. 63 (3) , 504-511
Adolescents and Bone Health
Adolescence is a critical time for the acquisition of peak bone mass. There are modifiable factors that may influence bone health in an adolescent. For those at risk for bone fragility, initial management includes optimization of calcium and vitamin D, weight-bearing exercise, and maintenance of a normal body weight. In certain scenarios, bisphosphonate treatment is indicated, as is reviewed. How hormonal contraceptives affect bone mineral density is unclear, but in patients with risk factors or known bone fragility, prescribers should consider their skeletal effects. Some conditions, including restrictive eating disorders and primary ovarian insufficiency, warrant long-term monitoring of bone health.
- Open Access
- 1 May 2020
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 145 (Supplement) , S210-S218
Diagnosis and Management of Polycystic Ovary Syndrome in Adolescents
Polycystic ovary syndrome (PCOS) is a common female reproductive disorder that often manifests during adolescence and is associated with disruptions in health-related quality of life. Prompt evaluation and clinical support after diagnosis may prevent associated complications and optimize overall health management. This article incorporates the most recent evidence and consensus guidelines to provide an updated review of the pathogenesis, clinical presentation, diagnostic evaluation, and management strategies for adolescents with this complex condition. We will review the recent international guidelines on PCOS; because the diagnosis of PCOS remains controversial, management of this condition is inconsistent. In 2019, PCOS remains a common, yet neglected, condition, in part, because of the lack of agreement around both diagnosis and management.
- 1 May 2020
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 145 (Supplement) , S210-S218
Open AccessDiagnosis and Management of Polycystic Ovary Syndrome in Adolescents
Polycystic ovary syndrome (PCOS) is a common female reproductive disorder that often manifests during adolescence and is associated with disruptions in health-related quality of life. Prompt evaluation and clinical support after diagnosis may prevent associated complications and optimize overall health management. This article incorporates the most recent evidence and consensus guidelines to provide an updated review of the pathogenesis, clinical presentation, diagnostic evaluation, and management strategies for adolescents with this complex condition. We will review the recent international guidelines on PCOS; because the diagnosis of PCOS remains controversial, management of this condition is inconsistent. In 2019, PCOS remains a common, yet neglected, condition, in part, because of the lack of agreement around both diagnosis and management.
- 29 May 2019
- Published by Springer Nature in Osteoporosis International
- Vol. 30 (8) , 1573-1580
A case-control pilot study of stress fracture in adolescent girls: the discriminative ability of two imaging technologies to classify at-risk athletes
Since stress fractures are common among adolescent athletes, it is important to identify bone assessment tools that accurately identify risk. We investigated the discriminative ability of two imaging technologies to classify at-risk athletes. Findings suggested that peripheral quantitative computed tomography (pQCT) has the ability to distinguish differences in bone structure in injured vs. uninjured limbs.
- 29 May 2019
- Published by Springer Nature in Osteoporosis International
- Vol. 30 (8) , 1573-1580
A case-control pilot study of stress fracture in adolescent girls: the discriminative ability of two imaging technologies to classify at-risk athletes
Since stress fractures are common among adolescent athletes, it is important to identify bone assessment tools that accurately identify risk. We investigated the discriminative ability of two imaging technologies to classify at-risk athletes. Findings suggested that peripheral quantitative computed tomography (pQCT) has the ability to distinguish differences in bone structure in injured vs. uninjured limbs.
- 28 March 2019
- Published by Springer Nature
- p. 269-277
Hypothalamic Amenorrhea
- Open Access
- 1 February 2019
- Published by Elsevier in Journal of Adolescent Health
- Vol. 64 (2) , S58-S59
112. Evaluation of A Health Education Module About Accessing Community Based Healthcare Services For Youth In A Juvenile Detention Facility
- 1 February 2019
- Published by Elsevier in Journal of Adolescent Health
- Vol. 64 (2) , S58-S59
Open Access112. Evaluation of A Health Education Module About Accessing Community Based Healthcare Services For Youth In A Juvenile Detention Facility
- 1 October 2017
- Published by SAGE Publications in Antiviral Therapy
- Vol. 23 (7) , 623-628
Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone
Background: Tenofovir disoproxil fumarate (TDF) increases serum parathyroid hormone (PTH) and 1,25 dihydroxy vitamin D (1,25-(OH) 2 D), and decreases bone mineral density (BMD). Optimal treatment of TDF-associated BMD loss requires an understanding of the primary cause of these abnormalities. Methods: Secondary review of data from two studies of TDF use in youth, comparing the relationship of PTH, 25-hydroxy vitamin D (25-OHD) and 1,25-(OH) 2 D in three groups with varying exposures to TDF: youth without HIV enrolled in a trial of TDF/emtricitabine (FTC) for HIV pre-exposure prophylaxis (PrEP) at baseline (no TDF exposure) and after 12 weeks of TDF (short-term TDF exposure); and youth with HIV treated with TDF-containing combination antiretroviral therapy (cART) for at least 6 months at study entry (long-term TDF exposure). Relationships were evaluated by correlation analyses. Results: Participants ranged in age from 17 to 24 years and >50% were Black/African American. In persons not treated with TDF, PTH had the physiologically appropriate negative correlation with 25-OHD (r=-0.3504, P=0.004). Correlations between PTH and 25-OHD in groups treated with TDF were weaker or absent. With longer term TDF treatment in persons with HIV, 25-OHD and 1,25-(OH) 2 D had the positive correlation similar to that found in vitamin D deficiency. Conclusions: TDF changes the relationship of 25-OHD to PTH, suggesting that in persons using TDF for PrEP or cART, a higher than usual target for serum 25-OHD concentration might be needed to reduce PTH and optimize bone health. Clinical trials registration: NCT01751646 (ATN 109) and NCT01769469 (ATN 117).
- 1 October 2017
- Published by SAGE Publications in Antiviral Therapy
- Vol. 23 (7) , 623-628
Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone
Background: Tenofovir disoproxil fumarate (TDF) increases serum parathyroid hormone (PTH) and 1,25 dihydroxy vitamin D (1,25-(OH) 2 D), and decreases bone mineral density (BMD). Optimal treatment of TDF-associated BMD loss requires an understanding of the primary cause of these abnormalities. Methods: Secondary review of data from two studies of TDF use in youth, comparing the relationship of PTH, 25-hydroxy vitamin D (25-OHD) and 1,25-(OH) 2 D in three groups with varying exposures to TDF: youth without HIV enrolled in a trial of TDF/emtricitabine (FTC) for HIV pre-exposure prophylaxis (PrEP) at baseline (no TDF exposure) and after 12 weeks of TDF (short-term TDF exposure); and youth with HIV treated with TDF-containing combination antiretroviral therapy (cART) for at least 6 months at study entry (long-term TDF exposure). Relationships were evaluated by correlation analyses. Results: Participants ranged in age from 17 to 24 years and >50% were Black/African American. In persons not treated with TDF, PTH had the physiologically appropriate negative correlation with 25-OHD (r=-0.3504, P=0.004). Correlations between PTH and 25-OHD in groups treated with TDF were weaker or absent. With longer term TDF treatment in persons with HIV, 25-OHD and 1,25-(OH) 2 D had the positive correlation similar to that found in vitamin D deficiency. Conclusions: TDF changes the relationship of 25-OHD to PTH, suggesting that in persons using TDF for PrEP or cART, a higher than usual target for serum 25-OHD concentration might be needed to reduce PTH and optimize bone health. Clinical trials registration: NCT01751646 (ATN 109) and NCT01769469 (ATN 117).
- 1 November 2015
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 70 (11) , 693-694
Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis
- 1 November 2015
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 70 (11) , 693-694
Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis